Proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates

资金收益用于支持针对PVR的领导计划的持续临床开发以及针对多个ADC候选人的IND支持活动

TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- Guangzhou-Israel Biotechnology Fund (GIBF) announced today that it has invested $10 million in Nectin Therapeutics Ltd. Nectin is a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments.

以色列特拉维夫，2024年5月6日/PRNewswire/--广州以色列生物技术基金（GIBF）今天宣布，它已向Nectin Therapeutics Ltd.投资1000万美元。Nectin是一家开发新型靶向免疫疗法的生物技术公司，可解决对批准的免疫肿瘤学治疗的耐药性。

The funds will be used to continue the development of Nectin's portfolio of novel immuno-oncology products, including the advancement of Nectin's ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug conjugate (ADC) portfolio..

这些资金将用于继续开发Nectin的新型免疫肿瘤学产品组合，包括推进Nectin正在进行的针对PVR的NTX1088全球1期临床试验及其抗药物偶联物（ADC）组合的临床前开发。。

Nectin is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into the nectin pathways to develop the next generation of immune oncology (IO) therapies. The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers.

Nectin是一家临床阶段的生物技术公司，致力于通过利用对Nectin途径的独特见解来开发下一代免疫肿瘤学（IO）疗法，从而改变癌症患者的生活。该公司的差异化疗法有可能为各种难以治疗的癌症的疗效和患者反应率制定新的标准。

Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates. It has a world-class scientific and management team with deep experience in oncology drug development and a successful track record in building biotechnology companies and developing innovative therapies.

Nectin的技术通过多种新型单克隆抗体和抗体-药物偶联物的管道解决了当前IO疗法的主要逃逸机制。它拥有一支世界级的科学和管理团队，在肿瘤药物开发方面拥有丰富经验，在建立生物技术公司和开发创新疗法方面有着成功的记录。

Nectin is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, Myeloma Investment Fund (MIF), and Cancer Focus Fund..

Nectin是一家由aMoon Fund、Peregrine Ventures、IBF、Integra Holdings、骨髓瘤投资基金（MIF）和癌症聚焦基金资助的风险投资支持的私人控股公司。。

NTX1088 is Nectin's First-in-Class lead candidate - a highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors. PVR blockade by NTX1088 is the first and only therapeutic approach aiming at restoring the antitumor immune activity of DNAM1 (CD226).

NTX1088是Nectin的第一类主要候选物-一种针对PVR（CD155）的高效单克隆抗体，PVR是一种在癌细胞上表达的跨膜蛋白，与PD1和PDL1免疫检查点抑制剂的耐药性有关。NTX1088阻断PVR是第一种也是唯一一种旨在恢复DNAM1（CD226）抗肿瘤免疫活性的治疗方法。

DNAM1 is a cell surface glycoprotein, central to the function of T and NK cells, that is suppressed by PVR on tumor cells. Restoring the expression and activation of DNAM1 by blocking PVR results in increased antitumor activity from T and NK cells. PVR blockade by NTX1088 further stimulates an antitumor immune response by preventing the suppressing signaling of several immune checkpoint receptors, including TIGIT and CD96..

DNAM1是一种细胞表面糖蛋白，对T细胞和NK细胞的功能至关重要，在肿瘤细胞上被PVR抑制。通过阻断PVR恢复DNAM1的表达和活化导致T细胞和NK细胞的抗肿瘤活性增加。NTX1088对PVR的阻断通过阻止几种免疫检查点受体（包括TIGIT和CD96）的抑制信号传导，进一步刺激了抗肿瘤免疫反应。。

PVR is overexpressed in many solid tumors across different cancer indications, including lung, colorectal, liver, ovarian, breast, adrenal, pancreatic, uterine, head and neck, gastric and esophageal cancers. High PVR expression is associated with poor prognosis and with resistance to PD1 and PDL1 blockade, making PVR an attractive target for both monotherapy and in combination with PD1 blockers, as is currently being clinically evaluated in the combination of NTX1088 and KEYTRUDA® (pembrolizumab)..

PVR在不同癌症适应症的许多实体瘤中过表达，包括肺癌，结直肠癌，肝癌，卵巢癌，乳腺癌，肾上腺癌，胰腺癌，子宫癌，头颈癌，胃癌和食道癌。高PVR表达与预后不良以及对PD1和PDL1阻断的抗性相关，使PVR成为单药治疗和与PD1阻断剂联合使用的有吸引力的靶标，目前正在临床评估NTX1088和KEYTRUDA®（pembrolizumab）的组合。。

'Nectin is working to usher in a new era of innovative immune-mediated cancer medicines and we are excited to back this important mission and team,' said Professor Shlomo Noy, Managing Partner and Chief Medical Officer of GIBF. 'We have been following the company closely as it continues to make meaningful progress across its portfolio as it develops transformational therapies that can improve the lives of many cancer patients and their treatment outcomes.'.

GIBF管理合伙人兼首席医疗官什洛莫·诺伊（ShlomoNoy）教授说，Nectin正在努力开创创新免疫介导癌症药物的新时代，我们很高兴支持这一重要使命和团队我们一直在密切关注该公司，因为它在其投资组合中继续取得有意义的进展，因为它开发了可以改善许多癌症患者生活及其治疗结果的转化疗法。”。

'We are grateful for the support from GIBF which reflects the rapid advancement of our anti-PVR clinical program as well as the progress in our development of several ADC candidates,' said Fabian Tenenbaum, CEO of Nectin Therapeutics. 'With this new investment we are looking forward to completing both the dose-escalation and dose-expansion trials for NTX1088 and continue our IND-enabling activities of our ADC assets.

Nectin Therapeutics首席执行官费边·特内鲍姆（FabianTenenbaum）说：“我们感谢GIBF的支持，这反映了我们抗PVR临床计划的快速发展以及我们在开发几种ADC候选药物方面取得的进展。”通过这项新的投资，我们期待着完成NTX1088的剂量递增和剂量扩展试验，并继续我们的ADC资产的IND支持活动。

We value GIBF's commitment to our mission of developing life-saving therapies and look forward to advancing innovative medicines to improve the lives of cancer patients.'.

我们重视GIBF对我们开发救生疗法的使命的承诺，并期待着推进创新药物以改善癌症患者的生活。”。

Contact:

联系人：

GIBF

钩头

Avner Lushi

Aver Lushi

Chief Executive Officer

首席执行官

avner@gibf-bio.com

avner@gibf-bio.com

View original content:https://www.prnewswire.com/news-releases/gibf-invests-10-million-in-nectin-therapeutics-to-advance-novel-pipeline-of-first-in-class-immunotherapies-and-antibody-drug-conjugates-302136519.html

查看原始内容：https://www.prnewswire.com/news-releases/gibf-invests-10-million-in-nectin-therapeutics-to-advance-novel-pipeline-of-first-in-class-immunotherapies-and-antibody-drug-conjugates-302136519.html

SOURCE The Guangzhou Sino-Israel Biotech Investment Fund (GIBF)

来源：广州中以生物技术投资基金（GIBF）